Thioridazine HCl, no NHI reimbursable from coming July.

As of July 1, the product registration of Thioridazine preparations (anti-psychotic drug) will be cancelled according to the KFDA and therefore its NHI reimbursement shall be also suspended, the Health Insurance Review Agency (HIRA) said.

Th KFDA said that the NHI reimbursed 6 brands of Thioridazine out of the total 9, 6 products of which are Mellibon tablet 50mg and 100mg of Myungin and Thi...